Shaukat Khanum Memorial Cancer Hospital and Research Centre

InterVenn Biosciences Announces the Publication of Early Detection of Advanced Adenoma and Colorectal Cancer in Gastroenterology, the Flagship Journal of the American Gastroenterological Association

Retrieved on: 
Friday, October 13, 2023

InterVenn Biosciences , a life sciences company pioneering glycoproteomics, today announced the publication of their discovery work in Advanced Adenoma (AA) and Colorectal Cancer (CRC) early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.

Key Points: 
  • InterVenn Biosciences , a life sciences company pioneering glycoproteomics, today announced the publication of their discovery work in Advanced Adenoma (AA) and Colorectal Cancer (CRC) early disease detection in the flagship journal of the American Gastroenterological Association, Gastroenterology.
  • This groundbreaking research in early detection of CRC represents an advancement in early diagnosis through serum glycoproteome profiling.
  • The results published in Gastroenterology establish the groundwork for a blood-based CRC screening modality using artificial intelligence to reveal the earliest stages of colorectal cancer.
  • Desai K, Gupta S, May FP, Xu G, Shaukat A, Hommes DW, NICE-AA/CRC- Consortium, Early detection of advanced adenomas and colorectal carcinoma by serum glycoproteome profiling., Gastroenterology (2023), doi: https://doi.org/10.1053/j.gastro.2023.09.034

The Shriners Hospitals for Children - Canada Research Centre celebrates half a century of existence

Retrieved on: 
Thursday, August 17, 2023

So research into mineralized tissue has always been a strength in Quebec," explains Professor René St-Arnaud, PhD, Director of the Research Center.

Key Points: 
  • So research into mineralized tissue has always been a strength in Quebec," explains Professor René St-Arnaud, PhD, Director of the Research Center.
  • In 1973, following the integration of Shriners Hospitals for Children – Canada into the Quebec health care network, Shriners Children’s management, with the approval of the provincial government, created the first Research Centre within its hospital network.
  • The Shriners Hospital for Children - Canada Research Centre is constantly developing new ways to care for children.
  • To mark this 50th anniversary at Shriners Hospital for Children – Canada, Dr. St-Arnaud hosted a scientific seminar yesterday featuring a number of prestigious speakers.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 20, 2022

This is the sixth indication approved for toripalimab in China and will bring more treatment options to Chinese patients with advanced NSCLC.

Key Points: 
  • This is the sixth indication approved for toripalimab in China and will bring more treatment options to Chinese patients with advanced NSCLC.
  • Professor Jie Wang from the Cancer Hospital, Chinese Academy of Medical Sciences elaborated on toripalimabs performance in clinical trials.
  • In China, the number of lung cancer patients is massive and so is the demand for treatment.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).

Sterotherapeutics Signs Licensing Agreement Aimed to Improve the Treatment of Multiple Myeloma

Retrieved on: 
Wednesday, March 30, 2022

"We are delighted to work with Sterotherapeutics to further develop this novel line of highly selective MMP-13 inhibitors for the treatment of multiple myeloma.

Key Points: 
  • "We are delighted to work with Sterotherapeutics to further develop this novel line of highly selective MMP-13 inhibitors for the treatment of multiple myeloma.
  • Multiple myeloma is a treatable, but incurable cancer of the bone marrow plasma cells.
  • SteroTherapeutics lead products have been proven in previous animal and human studies to possess a strong safety profile and established mechanisms of action.
  • In each individual disease target Sterotherapeutics embraces the opportunity to provide safe, effective treatments and restore an optimal quality of life.

Verde launches P4G shareholder earnings strategy after securing Banco do Brasil financing backed by future sales contracts

Retrieved on: 
Monday, January 24, 2022

Previously, financing could only be secured by invoice discounting or guaranteed by capital goods, now Verde's future sales contracts are accepted as debt collateral.

Key Points: 
  • Previously, financing could only be secured by invoice discounting or guaranteed by capital goods, now Verde's future sales contracts are accepted as debt collateral.
  • Banco do Brasil S.A. (BB) has granted to Verde a line of credit through Agribusiness Certificate of Credit Rights (CDCA, from Certificado de Direitos Creditrios do Agronegcio).
  • The guarantee of the operations are future sales contract with Verde.
  • P4G is being engineered in detail so that it can make the most of the Company's potential earnings without compromising its accelerated growth strategy.

ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 2, 2021

Cash and cash equivalents of $58.3 million at September 30, 2021, sufficient to fund operations through 2022

Key Points: 
  • Cash and cash equivalents of $58.3 million at September 30, 2021, sufficient to fund operations through 2022
    WESTMINSTER, Colo., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2021 financial results and provided a corporate update.
  • Our international Phase 2b clinical trial is nearing completion and we look forward to sharing its results in the first quarter.
  • Total operating expenses for the quarter ended September 30, 2021 were $4.7 million compared to $2.0 million for the third quarter of 2020.
  • ARCA biopharma is dedicated to developing genetically targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.

The Big Heart Foundation (TBHF): Wife of Sharjah Ruler announces USD 1.2 million grant to equip two operating theatres in Peshawar Cancer Hospital

Retrieved on: 
Monday, October 5, 2020

Around 2,500 cancer patients will benefit from access to a wide range of high-quality surgical treatment options at two fully equipped operating rooms fitted out with financial assistance from the Ameera Fund.

Key Points: 
  • Around 2,500 cancer patients will benefit from access to a wide range of high-quality surgical treatment options at two fully equipped operating rooms fitted out with financial assistance from the Ameera Fund.
  • Dr Faisal Sultan, CEO of the Shaukat Khanum Memorial Cancer Hospital & Research Centre (SKMCH&RC), on behalf of the hospital management, expressed gratitude for the contribution by the Ameera Fund.
  • He pointed out that the donation would take the centre a step forward towards its goal of alleviating the suffering of cancer patients and fulfilling their healthcare needs.
  • We consider every contribution, no matter how big or small, as a step forward to fostering the vision on which the hospital was established, while offering hope to our patients," he added.